Press Releases April 29, 2026 03:54 PM

Vornado Declares Quarterly Dividends On Preferred Shares

Vornado Realty Trust Declares Quarterly Dividends on Multiple Series of Preferred Shares

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
VNO

Vornado Realty Trust announced quarterly dividend declarations on multiple series of its preferred shares, with payments scheduled for July 1, 2026, to shareholders of record as of June 15, 2026. The company reiterated forward-looking statements highlighting risks related to interest rate fluctuations, inflation, and economic conditions affecting its business and tenants.

Vornado Declares Quarterly Dividends On Preferred Shares
VNO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Vornado declared quarterly preferred dividends on six series of preferred shares, specifying exact dividend amounts per share.
  • All dividends are payable on July 1, 2026, to shareholders recorded by June 15, 2026.
  • The company highlighted risks including interest rate fluctuations, inflation impacts, and economic uncertainties that may affect future performance.
  • This announcement directly impacts the real estate investment trust sector and financial markets involving preferred equity investments.

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) --

Vornado Realty Trust (NYSE:VNO) announced today that its Board of Trustees has declared the following quarterly preferred dividends:

 Series A Convertible$.8125000per share Series L Cumulative Redeemable$.3375000per share Series M Cumulative Redeemable$.3281250per share Series N Cumulative Redeemable$.3281250per share Series O Cumulative Redeemable$.2781250per share     

In each case, dividends are payable on July 1, 2026 to shareholders of record on June 15, 2026.

Vornado Realty Trust is a fully-integrated equity real estate investment trust.

CONTACT

Thomas J. Sanelli
(212) 894-7000

Certain statements contained herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance. They represent our intentions, plans, expectations and beliefs and are subject to numerous assumptions, risks and uncertainties. Our future results, financial condition and business may differ materially from those expressed in these forward-looking statements. You can find many of these statements by looking for words such as "approximates," "believes," "expects," "anticipates," "estimates," "intends," "plans," "would," "may" or other similar expressions in this press release. For a discussion of factors that could materially affect the outcome of our forward-looking statements and our future results and financial condition, see “Risk Factors” in Part I, Item 1A, of our Annual Report on Form 10-K for the year ended December 31, 2025. Currently, some of the factors are interest rate fluctuations and effects of inflation on our business, financial condition, results of operations, cash flows, operating performance and the effect that these factors have had and may continue to have on our tenants, the global, national, regional and local economies and financial markets and the real estate market in general.


Risks

  • Interest rate fluctuations may impact Vornado’s financial condition and operating performance.
  • Inflation effects could affect business results, cash flows, and tenant stability.
  • Economic uncertainties at global, national, regional, and local levels pose risks to real estate market performance and investor returns.

More from Press Releases

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026